Abstract
A method of inhibiting blood coagulation in a patient is provided. This method involves administering to the patient an effective anticoagulant amount of a cationic protein; wherein the cationic protein has an isoelectric point of at least about 7.4, and is capable of enhancing the production of activated protein C by a thrombomodulin-thrombin complex by a factor of at least about two. A particularly preferred cationic protein is purified Platelet Factor 4.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 766 |
| Number of pages | 1 |
| Journal | Biotechnology Advances |
| Volume | 15 |
| Issue number | 3-4 |
| DOIs | |
| State | Published - 1997 |
| Externally published | Yes |
Bibliographical note
Copyright:Copyright 2021 Elsevier B.V., All rights reserved.